ArticleMarine biotechnology (New York, N.Y.)2025
Terpenoids with Antiangiogenic Activity from Formosan Soft Coral Caementabunda hypotentaculata.
Article in Marine biotechnology (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Soft corals of the genus Caementabunda (synonym Cespitularia) were reported to possess terpenoids with various carbon skeletons. In this research, samples of C. hypotentaculata were collected before and after spawning (in May and August) to compare their secondary metabolites. With the aid of LC-MS/MS molecule networking, a series of unknown verticillane-type diterpenoids were targeted. After repeated column chromatography, five new verticillane-type diterpenoids (1‒5) and one new eudesmanolide-type sesquiterpenoid (6), together with twenty-four known compounds (7‒30), were identified from the Formosan soft coral C. hypotentaculata. Their structures were determined by UV, IR, MS, and NMR analyses, together with the biogenetic considerations of terpenoids. Our pharmacological study showed that the ethanol extract of C. hypotentaculata exhibited antiangiogenic potential against human endothelial progenitor cells. Among all isolated compounds, compound 30 demonstrated a moderate antiangiogenic effect with an IC
Indexed as
Identifiers
40178667What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.